Upcoming UCB dividend
Change(%)
+2.26%
Increase
Next payment 1.36€
Next payment date Apr 30, 2024
Last payment 1.33€
Last payment date May 3, 2023
00 D 00 H 00 M 00 S
Ex-Dividend: 4/26/24
Confirmed

With a dividend payment of 1,36 euros per share and a yield of 0.84%, UCB fulfills its shareholders on April 30, 2024.

To receive a dividend of 1,36 euros from UCB, purchase the shares before April 26, 2024 and stay until the Record Date, April 29, 2024.

On May 3, 2023, UCB made a dividend payment of 1.33 euros to its shareholders.

UCB S.A., listed on the stock exchanges of Brussels, Frankfurt, Vienna, BATS EU, OTC market, London and TradeGate, recognized with the stock exchange symbol UCB, has a track record of more than twenty years paying dividends to its shareholders without suspensions, starting in 1999 and has remained stable and consistent to date.

The value of the amount delivered has been maintained in a very approximate range for several periods, being settled in a single annual installment, usually granted in the first days of May, reaching a yield of approximately 1.20%.

Payout Ratio UCB Dividends

UCB paid 11% of its net income in the last fiscal period as dividends.
UCB's earnings (5,454,000,128.00€) are sufficient to cover the dividend payment. This payment represents 11% of the total net profit of UCB.
Dividend payout ratio
Payout Ratio

Dividend calendar of UCB

These are the most important events of the UCB calendar in 2024:

Event Day
Last trading date April 25, 2024
Ex-Dividend (Ex-Date) April 26, 2024
Record date April 29, 2024
Date of payment April 30, 2024
Data confirmed by the company UCB (UCB).
Confirmed
Source
Historical annual dividend yields of UCB
Over the past 5 years, UCB has steadily increased the annual dividend amount.
Increasing Dividends
Dividend yield
Dividend yield of UCB vs. the sector
UCB's dividend yield (0.84%) is below the sector average (1.23%).
Comparison with industry average
UCB's dividend yield is below the top 75% (1.23%) of the sector.
Evaluation with respect to competence.
Dividend yield history in UCB
In the last 5 years, UCB's annual dividend amount has not fallen more than 10%.
Dividend stability

Dividend history of UCB

In this table you can see the complete history:

YearEx-DividendAmountTotal
2023
04/28/2023
1.33 €
1.33 €
2022
04/29/2022
1.3 €
1.3 €
2021
04/30/2021
1.27 €
1.27 €
2020
05/04/2020
1.24 €
1.24 €
2019
04/26/2019
1.21 €
1.21 €
2018
04/27/2018
1.18 €
1.18 €
2017
04/28/2017
1.15 €
1.15 €
2016
04/29/2016
1.1 €
1.1 €
2015
05/04/2015
1.06 €
1.06 €
2014
04/29/2014
1.04 €
1.04 €
2013
05/02/2013
1.02 €
1.02 €
2012
04/27/2012
1. €
1 €
2011
05/02/2011
0.98 €
0.98 €
2010
05/03/2010
04/30/2010
0.96 €
0.96 €
1.92 €
2009
05/05/2009
0.92 €
0.92 €
2008
04/28/2008
0.92 €
0.92 €
2007
04/30/2007
0.9 €
0.9 €
2006
06/16/2006
0.88 €
0.88 €
2005
06/17/2005
0.86 €
0.86 €
2004
06/11/2004
04/21/2004
0.82 €
0.5 €
1.32 €
2003
06/13/2003
04/15/2003
0.8 €
0.41 €
1.21 €
2002
06/14/2002
04/17/2002
0.76 €
0.38 €
1.14 €
2001
06/14/2001
0.64 €
0.64 €
2000
06/14/2000
0.5 €
0.5 €
UCB dividend capture strategy
Step 1: Buy UCB shares (UCB) one day before ex-dividend date
Date of purchase Apr 25, 2024
Next ex-dividend date Apr 26, 2024
Step 2: Sell UCB shares (UCB) when the price recovers.
Date of sale (estimated) N/A
Average price recovery N/A
Average return on cost N/A
The dividend capture strategy is based on historical UCB data. Past performance is no guarantee of future results.

Information about UCB

Full name UCB SA
Ticker UCB
Sector Health Care
Industry Biotechnology
Market Capitalization 30.73B €
ISIN BE0003739530
Number of Employees 8,450
Description of the company

UCB S.A., a company dedicated to the health industry, specializing in the development of pharmaceutical products to treat serious, immunological and neurological diseases, with headquarters in Belgium, is present in 40 countries, with more than 8 thousand employees, registering 5.5 billion euros in sales in 2022.

It was founded in 1928 by Emmanuel Janssen, which was initially dedicated to the creation of industrial chemicals, being one of the first to distill ammonia from coal, also including a pharmaceutical laboratory, in 1950 created a research and development center where they produce key drugs for the company as Atarax, Piracetam or Nootropil and Zyrtec or cetirizine.

In 2002 they merged their previous activities and added others such as the creation of resins and additives, splitting the chemicals division in 2004, when they acquired the biotechnology company Celltech, in 2019 they bought Ra Pharma, a specialist in immunological diseases, and in 2022 they acquired Zogenix, remaining exclusively in the pharmaceutical sector.

The main products for which UCB is recognized are Atarax, Briviact, Nootropil, Zyrtec and Xyzal antihistamines, Keppra and Cimzia anticonvulsant drugs for the treatment of epilepsy, Vimpat an anticonvulsant, Atamet and Neupro used for Parkinson's disease.

Frequently asked questions about UCB dividends

UCB pays dividends on a Anual basis.

UCB is listed on the Bolsa de Bruselas and is part of the BEL20.

UCB has the Ticker or stock code UCB.

The CEO of UCB in 2024 is Mr. Jean-Christophe Tellier.

UCB has a growing dividend program. In the last 5 years, dividends have been at least equal to or higher than the previous year.

UCB ForumCheck the latest comments and participate in the live chat on UCB stocks (UCB).
Subscribe
Notify of
guest

0 Comments
Inline Feedbacks
View all comments